 The purpose of this study is to provide further immunogenicity and safety information of sanofi pasteurs DTacP-IPV combined vaccine TETRAXIMTM as a booster dose during the 4th and 6th year of life in children that previously received in Study E2I34 NCT 00255021, sanofi pasteur DTacP-IPV PRPT vaccine PENTAXIMTM as a three-dose primary and booster vaccinations. 